Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors.

4th Fabisch-Symposium for Cancer Research and Molecular Cell Biology, 2nd Targeted Tumor Therapies: 01-03 April 2009, Berlin, Germany

2nd NIH Mesothelioma Conference: March 6, 2009 - Lipsett Auditorium - National Institutes of Health - Bethesda, MD